Cargando…

Treatment persistence in patients with type 2 diabetes treated with glucagon‐like peptide‐1 receptor agonists in clinical practice in Sweden

AIM: To compare treatment persistence in patients with type 2 diabetes initiating the glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) dulaglutide, exenatide once‐weekly (QW), liraglutide or lixisenatide in routine clinical practice in Sweden and assess clinical outcomes. MATERIALS AND METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Svensson, Ann‐Marie, Toll, Anders, Lebrec, Jeremie, Miftaraj, Mervete, Franzén, Stefan, Eliasson, Björn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7953897/ https://www.ncbi.nlm.nih.gov/pubmed/33289287 http://dx.doi.org/10.1111/dom.14276

Ejemplares similares

Clinical effects, cardiovascular and renal outcomes associated with rapid-acting insulin analogs among individuals with type 2 diabetes: a nation-wide observational cohort study
por: Svensson, Ann-Marie, et al.
Publicado: (2017)

Risk of cardiovascular event and mortality in relation to refill and guideline adherence to lipid-lowering medications among patients with type 2 diabetes mellitus in Sweden
por: Karlsson, Sofia Axia, et al.
Publicado: (2019)

SAT-378 Thyroid Disease, a Severe Infection, and Glucagon Prescription Should Raise the Awareness of Addison's Disease in Patients with Type 1 Diabetes: A National Swedish Study
por: Chantzichristos, Dimitrios, et al.
Publicado: (2019)

Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study
por: Lugner, Moa, et al.
Publicado: (2021)

Persistence with IDegLira in Patients in Clinical Practice: A Nationwide Observational Study in Sweden
por: Eliasson, Björn, et al.
Publicado: (2020)

Clinical Effects and Safety of Direct-Acting Insulin Analogs in Patients with Type 1 Diabetes: A Nation-Wide Observational Cohort Study
por: Lak, Vincent, et al.
Publicado: (2016)

Efficacy and Safety of Treatment with New Basal Insulin Analogues in Type 1 Diabetes: Nation-Wide Survey
por: Svensson, Ann-Marie, et al.
Publicado: (2020)

Prescription of lipid-lowering medications for patients with type 2 diabetes mellitus and risk-associated LDL cholesterol: a nationwide study of guideline adherence from the Swedish National Diabetes Register
por: Karlsson, Sofia Axia, et al.
Publicado: (2018)

Impact of Socioeconomic Factors and Gender on Refill Adherence and Persistence to Lipid-Lowering Therapy in Type 1 Diabetes
por: Hero, Christel, et al.
Publicado: (2021)

Refill adherence and persistence to lipid‐lowering medicines in patients with type 2 diabetes: A nation‐wide register‐based study
por: Karlsson, Sofia Axia, et al.
Publicado: (2017)

Cardiovascular Disease in Patients with Type 2 Diabetes and in Patients Starting Empagliflozin Treatment: Nationwide Survey
por: Eliasson, Björn, et al.
Publicado: (2019)

Pros and cons of gastric bypass surgery in individuals with obesity and type 2 diabetes: nationwide, matched, observational cohort study
por: Liakopoulos, Vasileios, et al.
Publicado: (2019)

Potential Effects of Bariatric Surgery on the Incidence of Heart Failure and Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus and Obesity and on Mortality in Patients With Preexisting Heart Failure: A Nationwide, Matched, Observational Cohort Study
por: Höskuldsdóttir, Gudrún, et al.
Publicado: (2021)

Comparison between data-driven clusters and models based on clinical features to predict outcomes in type 2 diabetes: nationwide observational study
por: Lugner, Moa, et al.
Publicado: (2021)

Diabetes mellitus was not associated with lower amputation-free survival after open revascularization for chronic limb-threatening ischemia – A nationwide propensity score adjusted analysis
por: Lilja, Erika, et al.
Publicado: (2021)

Association between refill adherence to lipid-lowering medications and the risk of cardiovascular disease and mortality in Swedish patients with type 2 diabetes mellitus: a nationwide cohort study
por: Karlsson, Sofia Axia, et al.
Publicado: (2018)

Adherence to lipid-lowering therapy and risk for cardiovascular disease and death in type 1 diabetes mellitus: a population-based study from the Swedish National Diabetes Register
por: Hero, Christel, et al.
Publicado: (2020)

Worse cardiovascular prognosis after endovascular surgery for intermittent claudication caused by infrainguinal atherosclerotic disease in patients with diabetes
por: Dakhel, Ardwan, et al.
Publicado: (2020)

Range of Risk Factor Levels: Control, Mortality, and Cardiovascular Outcomes in Type 1 Diabetes Mellitus
por: Rawshani, Aidin, et al.
Publicado: (2017)

Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes Mellitus: Data from a Real-World Study in Spain
por: Norrbacka, Kirsi, et al.
Publicado: (2021)

Durability of oral hypoglycemic agents in drug naïve patients with type 2 diabetes: report from the Swedish National Diabetes Register (NDR)
por: Ekström, Nils, et al.
Publicado: (2015)

Cost–Utility Analysis of Glucagon-Like Peptide-1 Agonists Compared with Dipeptidyl Peptidase-4 Inhibitors or Neutral Protamine Hagedorn Basal Insulin as Add-On to Metformin in Type 2 Diabetes in Sweden
por: Kiadaliri, Aliasghar A., et al.
Publicado: (2014)

Utilization Patterns of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus in Italy: A Retrospective Cohort Study
por: Federici, Marco Orsini, et al.
Publicado: (2018)

Aspirin treatment and risk of first incident cardiovascular diseases in patients with type 2 diabetes: an observational study from the Swedish National Diabetes Register
por: Ekström, Nils, et al.
Publicado: (2013)

Effect of flash glucose monitoring in adults with type 1 diabetes: a nationwide, longitudinal observational study of 14,372 flash users compared with 7691 glucose sensor naive controls
por: Nathanson, David, et al.
Publicado: (2021)

Clinical Use and Effectiveness of Lipid Lowering Therapies in Diabetes Mellitus—An Observational Study from the Swedish National Diabetes Register
por: Eliasson, Björn, et al.
Publicado: (2011)

Glucagon-like peptide-1 receptor agonists in patients treated with antipsychotics
por: Delgado, A., et al.
Publicado: (2021)

Body mass index as a risk factor for coronary events and mortality in patients with type 1 diabetes
por: Vestberg, Daniel, et al.
Publicado: (2018)

Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease
por: Baggio, Laurie L., et al.
Publicado: (2020)

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
por: Lee, Seungah, et al.
Publicado: (2017)

Blood pressure and complications in individuals with type 2 diabetes and no previous cardiovascular disease: national population based cohort study
por: Adamsson Eryd, Samuel, et al.
Publicado: (2016)

Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists
por: Kang, Yu Mi, et al.
Publicado: (2016)

How glucagon-like peptide 1 receptor agonists work
por: Andreasen, Christine Rode, et al.
Publicado: (2021)

Synthesis and biological evaluation of glucagon-like peptide-1 receptor agonists
por: Zhang, Yu-Juan, et al.
Publicado: (2013)

Glucagon‐like peptide‐1 receptor agonists and their effects on weight reduction
por: Shin, Shyi‐Jang
Publicado: (2012)

Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes
por: Hinnen, Deborah
Publicado: (2017)

The potential of glucagon-like peptide-1 receptor agonists in heart failure
por: Kreiner, Frederik Flindt, et al.
Publicado: (2022)

Glucagon-Like Peptide-1 Receptor Agonists for Chronic Weight Management
por: Wojtara, Magda, et al.
Publicado: (2023)

Association of glucagon‐like peptide‐1 receptor‐targeted imaging probe with in vivo glucagon‐like peptide‐1 receptor agonist glucose‐lowering effects
por: Murakami, Takaaki, et al.
Publicado: (2020)

Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists
por: Saraiva, Francisco Kerr, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_t3q948aq76nvbpmvd7l3icp6ou